Browse video insights from healthcare professionals and actual TYSABRI patients on managing relapsing MS and treatment with TYSABRI.
Simon Fishman, MD, highlights the importance of early intervention with DMT to help delay the progression of MS.
Charles Smith, MD, explains how ongoing activity on MRI may be indicative of a poor long-term prognosis.
Leading physicians discuss the need to monitor disease activity to help guide treatment decisions.
Karen Blitz-Shabbir, DO, shares how she uses MRI to identify ongoing subclinical disease activity in clinically stable patients.
Patient Keith describes his experience with MS and taking action against the disease as well as the impact of delayed treatment.
Leading physicians recount personal experiences in treating patients with active disease who responded well to TYSABRI.
Leading physicians describe the value of real-world experience (10+ years) when considering an appropriate DMT.
Stephen Newman, MD, and patient Jennifer discuss evidence from the clinical trial as it relates to their own experiences with TYSABRI.
Christopher LaGanke, MD, outlines a full assessment of the benefits of therapy in the context of PML risk and MS progression.
Christopher LaGanke, MD, describes ongoing conversations with JCV+ patients about treatment benefits, PML risk, and MS progression
Karen-Blitz-Shabbir, DO advises her patients about certain risks of treatment that may be associated with TYSABRI.
Regina Berkovich, MD, PhD, advocates for involving patients in making an informed decision to continue TYSABRI, regardless of JCV status.
Stephen Newman, MD, and patient Jennifer describe the positive atmosphere, infusion process, and patient-nurse interactions at a center.
Patient Bryan describes his journey with RMS before and after starting treatment with TYSABRI.
HCPs and patient Heidi detail the infusion experience, highlighting the partnership and patient support evident at each center.